CROSSCHECK-001
A Study of CBX-250 in Participants With Relapsed or Refractory Myeloid Leukemias (CROSSCHECK-001)
What will happen during the trial?
Participants aged ≥ 12 years are planned to be enrolled. CBX-250 will initially be investigated on a fixed step-up dosing schedule. CBX-250 will be administered subcutaneously in 28-day cycles, with the first study drug dose administered on Cycle 1, Day 1. Cycle 1 will consist of a priming phase over 7 days, and a target phase over 28 days. Participants will continue CBX-250 until progressive disease (PD) or unacceptable toxicity. All subsequent treatment cycles will be 28 days.
More Information
- Trial Status
- Accepting patients
- Trial Phase
- Phase 1
- Enrollment
- 72 patients (estimated)
- Sponsors
- Crossbow Therapeutics, Inc.
- Tags
- T Cell Engager (TCE), Cathepsin G (CTSG), High Risk
- Trial Type
- Treatment
- Last Update
- SparkCures ID
- 2142
- NCT Identifier
- NCT06994676
Real People. Real Support.
Need help connecting with this clinical trial? We're here to help!
Print a patient-friendly report to share with your patient.
We can help answer any questions and connect you (or your patient) with the study team.
Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.